TYK Medicines, Inc
浙江同源康醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2410)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025; RESIGNATION OF NON-EXECUTIVE DIRECTOR;AND PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

FINANCIAL HIGHLIGHTS

	Six months ended June 30,			
	2025	2024	Changes	
	RMB'000	*RMB'000*	*RMB'000*	*%*
	(Unaudited)	*(Unaudited)*		
Research and development costs	**(88,758)**	(137,758)	49,000	-35.6
Administrative expenses	**(38,775)**	(40,100)	1,325	-3.3
Total comprehensive loss for the period	**(114,065)**	(219,533)	105,468	-48.0

INTERIM RESULTS

The Board is pleased to announce the unaudited condensed consolidated interim results of the Group for the six months ended June 30, 2025, together with the comparative figures for the corresponding period in 2024. The unaudited condensed consolidated financial statements of the Group for the Reporting Period have been reviewed by the Audit Committee.

Certain amounts and percentage figures included in this announcement have been subject to rounding adjustments, or have been rounded to one or two decimal places. Any discrepancies in any table, chart or elsewhere between totals and sums of amounts listed therein are due to rounding.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended June 30, 2025

	Notes	For the six months ended June 30, 2025 **RMB'000 (Unaudited)**	2024 RMB'000 (Unaudited)
Revenue		**–**	–
Cost of sales		**–**	–
GROSS PROFIT		**–**	–
Other income and gains	4	**20,820**	11,285
Research and development costs		**(88,758)**	(137,758)
Administrative expenses		**(38,775)**	(40,100)
Other expenses and losses	5	**(3)**	(70)
Finance costs	7	**(7,349)**	(5,431)
Change in fair value of redemption liabilities on equity shares		**–**	(47,459)
LOSS BEFORE TAX	6	**(114,065)**	(219,533)
Income tax expense	8	**–**	–
LOSS FOR THE PERIOD		**(114,065)**	(219,533)
Attributable to:			
Owners of the Company		**(112,177)**	(219,053)
Non-controlling interests		**(1,888)**	(480)
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD		**(114,065)**	(219,533)
Attributable to:			
Owners of the Company		**(112,177)**	(219,053)
Non-controlling interests		**(1,888)**	(480)
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE COMPANY			
Basic and diluted (expressed in RMB)	9	**(0.30)**	(0.68)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at June 30, 2025

	Notes	**As at June 30, 2025** ***RMB'000*** ***(Unaudited)***	As at December 31, 2024 *RMB'000* *(Audited)*
NON-CURRENT ASSETS			
Property, plant and equipment	*10*	**168,993**	159,575
Right-of-use assets	*11*	**43,549**	50,260
Intangible assets		**59,583**	62,412
Investment in a joint venture		**2,000**	–
Prepayments and other receivables		**36,998**	74,471
Total non-current assets		**311,123**	346,718
CURRENT ASSETS			
Prepayments and other receivables		**90,368**	76,175
Financial assets at fair value through profit and loss ("**FVTPL**")	*12*	**186,848**	–
Cash and bank balances	*13*	**206,082**	460,463
		483,298	536,638
Assets of a disposal company classified as held for sale		**–**	32,337
Total current assets		**483,298**	568,975
CURRENT LIABILITIES			
Trade and other payables	*14*	**102,864**	118,706
Interest-bearing bank and other borrowings		**130,855**	144,175
Lease liabilities	*11*	**25,612**	26,188
		259,331	289,069
Liabilities directly associated with the assets classified as held for sale		**–**	12
Total current liabilities		**259,331**	289,081
NET CURRENT ASSETS		**223,967**	279,894
TOTAL ASSETS LESS CURRENT LIABILITIES		**535,090**	626,612

	Notes	**As at June 30, 2025** ***RMB'000*** ***(Unaudited)***	As at December 31, 2024 *RMB'000* *(Audited)*
NON-CURRENT LIABILITIES			
Deferred income	*15*	**44,342**	44,360
Other long-term payables	*16*	**118,866**	103,205
Lease liabilities	*11*	**5,379**	6,485
Interest-bearing bank and other borrowings		**8,006**	–
Total non-current liabilities		**176,593**	154,050
Net assets		**358,497**	472,562
EQUITY			
Equity attributable to owners of the Company			
Share capital		**370,836**	370,836
Reserves		**(13,925)**	98,252
		356,911	469,088
Non-controlling interests		**1,586**	3,474
Total equity		**358,497**	472,562

1. CORPORATE AND GROUP INFORMATION

The Company was incorporated in the PRC on November 2, 2017, and its H shares were listed on the Main Board of the Stock Exchange since August 20, 2024. The registered office address of the Company is Room 1403-2, 14th Floor, Tower A, Changxing World Trade Building, No.1278 Mingzhu Road, Changxing Economic Development Zone, Changxing County, Huzhou, Zhejiang Province, the PRC.

The Company is a drug discovery research and development centre. The Group is principally engaged in the research, development and commercialization of pharmaceutical products.

2.1 BASIS OF PREPARATION

The interim condensed consolidated financial information for the six months period ended June 30, 2025 has been prepared in accordance with HKAS 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the consolidated financial statements of the Company for the year ended December 31, 2024.

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended December 31, 2024, except for the adoption of the following amended HKFRS Accounting Standard for the first time for the current period's financial information.

Amendments to HKAS 21	*Lack of Exchangeability*

The nature and the impact of the amended HKFRS Accounting Standard are described below:

Amendments to HKAS 21 specify how an entity shall assess whether a currency is exchangeable into another currency and how it shall estimate a spot exchange rate at a measurement date when exchangeability is lacking. The amendments require disclosures of information that enable users of financial statements to understand the impact of a currency not being exchangeable. As the currencies that the Group had transacted with and the functional currencies of group entities for translation into the Group's presentation currency were exchangeable, the amendments did not have any impact on the interim condensed consolidated financial information.

3. OPERATING SEGMENT INFORMATION

For management purposes, the Group has only one reportable operating segment, which is the development and commercialization of pharmaceutical products. Since this is the only reportable operating segment of the Group, no further operating segment analysis thereof is presented.

Geographical information

Since all of the Group's non-current assets were located in the PRC, no geographical information in accordance with HKFRS 8 *Operating Segments* is presented.

4. OTHER INCOME AND GAINS

An analysis of other income and gains is as follows:

	For the six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	*(Unaudited)*
Other income		
Government grants related to income	**12,206**	6,336
Government grants related to interest-free financing	**4,381**	3,516
Bank interest income	**800**	817
Gains		
Investment income on financial assets at FVTPL	**5,082**	372
Gain on fair value changes of financial assets at FVTPL	**–**	263
Gain on termination of a lease contract	**–**	2
Foreign exchange losses, net	**(1,649)**	(21)
Total	**20,820**	11,285

5. OTHER EXPENSES AND LOSSES

	For the six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	*(Unaudited)*
Loss on disposals of property, plant and equipment	**1**	–
Others	**2**	70
Total	**3**	70

6. LOSS BEFORE TAX

The Group's loss before tax is arrived at after charging:

	For the six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	*(Unaudited)*
Depreciation of property, plant and equipment*	**3,408**	4,702
Depreciation of right-of-use assets**	**6,444**	7,196
Amortisation of intangible assets***	**2,829**	2,829
Research and development costs	**63,011**	107,993
Loss on disposal of items of property, plant and equipment	**1**	–
Expenses relating to short-term leases	**844**	477
Listing expenses	**–**	12,632
Staff costs (including directors' emoluments)****:		
Salaries, discretionary bonuses, allowances and benefits in kind	**29,007**	24,500
Pension scheme contributions	**1,484**	1,274
Share-based payment compensation	**–**	7,035
Total	**30,491**	32,809

* The depreciation of property, plant and equipment is included in "Research and development costs" and "Administrative expenses" in profit or loss.

** The depreciation of right-of-use assets is included in "Research and development costs" and "Administrative expenses" in profit or loss.

*** The amortisation of intellectual property is included in "Research and development costs" in profit or loss.

**** The staff cost is included in "Research and development costs" and "Administrative expenses" in profit or loss.

7. FINANCE COSTS

	For the six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	*(Unaudited)*
Interest on lease liabilities (Note 11)	**479**	816
Interest expenses on government grants	**4,550**	3,671
Interest on bank loans	**2,320**	944
Total	**7,349**	5,431

8. INCOME TAX EXPENSE

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

Mainland China

Under the Law (the "**EIT Law**") of the PRC on Enterprise Income Tax (the "**EIT**") and Implementation Regulation of the EIT Law, the EIT rate of the PRC subsidiaries was 25% during the six months ended June 30, 2025 except for the Company which was subject to tax concession as set out below.

The Company was accredited as a "High and New Technology Enterprise" ("**HNTE**") in 2022. Therefore, the Company was entitled to a preferential EIT rate of 15% for a three-year period since 2022. The qualification as an HNTE is subject to review by the relevant tax authority in the PRC every three years.

9. LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE COMPANY

The calculation of the basic loss per share amount is based on the loss for the period attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 370,836,000 (six months ended June 30, 2024: 320,356,000) outstanding during the period.

The Group had no potentially dilutive ordinary shares outstanding during the period.

The calculation of basic and diluted loss per share is based on:

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	*(Unaudited)*
Loss		
Loss attributable to ordinary equity holders of the parent	**(112,177)**	(219,053)
Shares		
Weighted average number of ordinary shares in issue during the period used in the basic loss per share calculation	**370,836,000**	320,356,000
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT (Express in RMB)		
Basic and diluted	**(0.30)**	(0.68)

10. PROPERTY, PLANT AND EQUIPMENT

During the six months ended June 30, 2025, the Group acquired assets at a cost of RMB12,827,000 (unaudited) (six months ended June 30, 2024: RMB8,519,000 (unaudited)). Assets (other than those classified as held for sale) with a net book value of RMB1,000 (unaudited) were disposed of by the Group during the six months ended June 30, 2025 (six months ended June 30, 2024: RMB4,760,000 (unaudited)).

No impairment loss was recognised during the six months ended June 30, 2025.

11. LEASES

The Group as a lessee

The Group has lease contracts for land use right and various items of office premises used in its operations. Land use right has term for usage of approximately 20 to 50 years and leases of office premises generally have lease terms between 2 and 5 years. Generally, the Group is restricted from assigning and subleasing the leased assets outside the Group.

(a) Right-of-use assets

	For the six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	*(Unaudited)*
At beginning of the period	**50,260**	92,335
Depreciation charge	**(6,711)**	(7,463)
Disposals	**–**	(199)
At end of the period	**43,549**	84,673

(b) Lease liabilities

The carrying amounts of lease liabilities and the movements during the period are as follows:

	For the six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	*(Unaudited)*
Carrying amount at beginning of the period	**32,673**	41,729
Accretion of interest recognised during the period	**479**	816
Lease termination	**–**	(201)
Payments	**(2,161)**	(2,106)
Carrying amount at end of the period	**30,991**	40,238

(c) The amounts recognised in profit or loss in relation to leases are as follows:

	For the six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	*(Unaudited)*
Interest on lease liabilities	**479**	816
Depreciation charge of right-of-use assets	**6,444**	7,196
Short-term lease expenses	**844**	477
Lease termination	**–**	(2)
Total	**7,767**	8,487

12. FINANCIAL ASSETS AT FVTPL

	As at June 30, 2025	As at December 31, 2024
	RMB'000	*RMB'000*
	(Unaudited)	*(Audited)*
Wealth management products	**186,848**	–

13. CASH AND CASH EQUIVALENTS

	As at June 30, 2025	As at December 31, 2024
	RMB'000	*RMB'000*
	(Unaudited)	*(Audited)*
Cash and bank balances	**206,082**	460,463
Less:		
Time deposits over three months (i)	**(50,000)**	(60,475)
Pledged deposits (ii)	**(25,000)**	(25,000)
Cash and cash equivalents	**131,082**	374,988

(i) They represent time deposits with initial terms of over three months when acquired in commercial banks with annual return rates of 1.55% (for the year ended December 31, 2024: from 1.45% and 1.55%). None of these deposits are either past due or impaired. None of these deposits are pledged.

(ii) They represent pledged deposits in a commercial bank for a bank loan. None of these deposits are either past due or impaired.

Denominated in		
RMB	**38,378**	90,597
USD	**545**	3,479
HKD	**92,159**	280,912

The RMB is not freely convertible into other currencies, however, under China's Foreign Exchange Control Regulations and Administration of Settlement, Sale and Payment of Foreign Exchange Regulations, the Group is permitted to exchange RMB for other currencies through banks authorised to conduct foreign exchange business.

Cash at banks earns interest at floating rates based on daily bank deposit rates. Short term time deposits are made for varying periods of between one day and three months depending on the immediate cash requirements of the Group, and earn interest at the respective short term time deposit rates. The bank balances and pledged deposits are deposited with creditworthy banks with no recent history of default.

14. TRADE AND OTHER PAYABLES

	June 30, 2025	December 31, 2024
	RMB'000	*RMB'000*
	(Unaudited)	*(Audited)*
Trade payables	**14,146**	19,642
Payroll payables	**4,416**	4,251
Accrued expenses for research and development services	**49,385**	41,463
Accrued listing expenses	**1,688**	2,204
Other taxes payables	**7**	6,975
Other payables		
– Payables for property, plant and equipment	**30,590**	29,299
– Advance receivable from disposing a subsidiary	**–**	10,000
– Others	**2,632**	4,872
Total	**102,864**	118,706

An ageing analysis of the trade payables as at the end of the Reporting Period, based on the invoice date, is as follows:

	June 30, 2025	December 31, 2024
	RMB'000	*RMB'000*
	(Unaudited)	*(Audited)*
Within 3 months	**11,115**	15,115
3 to 6 months	**1,542**	3,297
6 months to 1 year	**1,002**	1,202
Over 1 year	**487**	28
Total	**14,146**	19,642

The trade payables are non-interest-bearing and payable on demand, which are normally settled on terms of 1 to 3 months.

15. DEFERRED INCOME

	As at June 30, 2025 ***RMB'000*** ***(Unaudited)***	As at December 31, 2024 *RMB'000* *(Audited)*
Government grants related to interest-free financing	**44,342**	43,821
Government grants related to income*	**–**	539
Total	**44,342**	44,360

* The movements in deferred income during the period/year are as follows:

	As at June 30, 2025 ***RMB'000*** ***(Unaudited)***	As at December 31, 2024 *RMB'000* *(Audited)*
At beginning of the period/year	**539**	2,982
Grants received during the period/year	**4,334**	4,540
Amounts released to profit or loss during the period/year	**(4,873)**	(6,983)
At end of the period/year	**–**	539

16. OTHER LONG-TERM PAYABLES

	As at June 30, 2025 ***RMB'000*** ***(Unaudited)***	As at December 31, 2024 *RMB'000* *(Audited)*
Government funding	**118,866**	103,205

17. DIVIDENDS

No dividend was paid or declared by the Company during the six months ended June 30, 2025 (six months ended June 30, 2024: Nil).

BUSINESS HIGHLIGHTS

During the Reporting Period and up to the date of this announcement, we have made the following progress with respect to our product pipeline and business operations:

- **Critical Developments of Our Core Product TY-9591**

  We commenced the subject enrollment for a pivotal Phase II clinical trial of TY-9591 monotherapy as first-line treatment in brain metastases from lung cancer with EGFR mutations in August 2023. In November 2024, we completed an enrollment of 224 patients that is qualified for conditional marketing approval (patient enrollment qualified for full marketing approval is still ongoing). We have submitted the relevant Pre-NDA application in April 2025 and expect to formally submit an NDA application for conditional marketing in the fourth quarter (Q4) of 2025. In addition, we are currently conducting a registrational Phase III clinical trial of TY-9591 monotherapy as first-line treatment in locally advanced (stage IIIb to IV) or metastatic lung cancer with EGFR L858R mutation in the PRC, for which we completed a patient enrollment of 541 subjects by the end of July 2025. We expect to complete the enrollment of all patients for this clinical trial in the second quarter (Q2) of 2026 and to submit NDA in 2028. To fully explore the potential of TY-9591, we also applied for and obtained IND approval for conducting Phase II and Phase III clinical trials of TY-9591 in combination with pemetrexed and cisplatin or carboplatin as first-line treatment in advanced or metastatic lung cancer with EGFR mutations in March 2024. Up to the date of this announcement, we did not receive any concerns or objections regarding our clinical development plans from the NMPA. We started the preparation for Phase II trial in November 2024 and officially initiated the site in February 2025. As of August 2025, patient enrollment has been completed. We expect to complete the preliminary data cleansing and analysis for the Phase II trial by Q4 2025 and to communicate with CDE for confirmatory clinical study in the first quarter (Q1) of 2026.

- **Critical Developments of Our Key Product TY-302**

  We are currently conducting a Phase II clinical trial of TY-302 as treatment for breast cancer. Approval for a Phase II clinical trial of TY-302 in combination with abiraterone for the first-line treatment of prostate cancer was granted by the hospital ethics committee on July 10, 2025, and the trial was publicly registered on the CDE Clinical Trial Registration Platform on July 28, 2025.

- **Critical Developments of Our Key Product TY-2136b**

  We obtained implied IND approval from the FDA in November 2021 and is conducting a Phase I clinical trial in the U.S. Leveraging Phase I clinical data collected, we plan to communicate with the FDA and carefully design our future clinical development plan of TY-2136b in the U.S.

- **Critical Developments of Other Drug Candidates**

TY-2699a

In January 2025, we obtained an approval from the NMPA for a clinical trial of TY-2699a in combination with various dosing regimens for the treatment of advanced/metastatic solid tumors (breast cancer, pancreatic cancer, and head and neck squamous cell carcinoma (HNSCC) such as nasopharyngeal carcinoma (NPC)). As of June 2025, the Phase I dose-escalation clinical trial of TY-2699a monotherapy for locally advanced or metastatic solid tumors (especially for HR+/HER2-breast cancer, triple-negative breast cancer (TNBC), SCLC, pancreatic cancer and head and neck cancer, etc.) has been completed. A total of 30 patients were enrolled across 7 dose groups (5mg, 10mg, 20mg, 40mg and 30mg, bid, on a continuous schedule; and 25 mg, 35 mg, bid, on a 5-day-on/2-day-off schedule) for the single-dose escalation studies. The extension study of monotherapy for triple-negative breast cancer (TNBC) was initiated in July 2025 and is currently enrolling patients.

TY-0540

A formal approval was obtained from the NMPA in February 2025 for TY-0540 to be used in the clinical trials of TY-0540 in combination with Fulvestrant (氟維司群) for the treatment in patients with locally advanced/recurring metastatic breast cancer and the clinical trials of TY-0540 in combination with Enzalutamide (恩扎盧胺) for the treatment in patients with locally advanced/recurring metastatic pancreatic cancer. In February 2025, the Phase I dose-escalation clinical trial of TY-0540 monotherapy for advanced solid tumors was completed, with dose-escalation studies completed for 5 dose groups (5mg, 10mg, 20mg, 30mg and 40mg, bid). At the Phase I dose-escalation stage, 24 patients were enrolled, including 15 with HR+/HER2- breast cancer, 5 with triple-negative breast cancer, 2 with platinum-resistant ovarian cancer, and 1 each with HR+/HER2+ breast cancer and non-small cell lung cancer. 2 patients with CDK4/6 inhibitor-resistant HR+/HER2- breast cancer and 1 with platinum-resistant ovarian cancer achieved partial response (PR). The extended cohort studies of monotherapy (30mg) for breast cancer and ovarian cancer was officially initiated in March 2025 and the clinical study of TY-0540 in combination with Fulvestrant (氟維司群) for the treatment of breast cancer was officially initiated in June 2025. Approval for the clinical study of TY-0540 in combination with Enzalutamide (恩扎盧胺) for the treatment of pancreatic cancer was granted by the hospital ethics committee on July 10, 2025, and the study was publicly registered on the CDE Clinical Trial Registration Platform on July 25, 2025.

TY-1091

We are currently conducting a Phase I clinical trial of TY-1091 for the treatment of RET fusion-positive solid tumors in China.

TY-4028

We obtained implied IND approval from the FDA and IND approval from the NMPA in April 2023 and June 2023, respectively.

TY-1054

We obtained implied approval from the FDA for conducting a clinical trial of TY-1054 for the treatment of solid tumors in April 2024. In addition, we submitted an IND application to the NMPA for conducting a clinical trial of TY-1054 for the treatment of solid tumors in April 2024, and obtained IND approval in July 2024.

I. BUSINESS REVIEW

Overview

We are a biopharmaceutical company that is about to enter the commercialization stage, committed to the discovery, acquisition, development and commercialization of differentiated targeted therapies to address unmet medical needs in cancer treatment. Since our inception in 2017, we have built a pipeline with 11 drug candidates, including Core Product TY-9591, seven clinical stage products, and three preclinical stage or early clinical development stage products. We are currently preparing an NDA application for conditional marketing of TY-9591 as first-line treatment of brain metastases from lung cancer with epidermal growth factor receptor ("**EGFR**") mutations, as well as a registrational Phase III clinical trial of TY-9591 monotherapy as first-line treatment in locally advanced (stage IIIb to IV) or metastatic NSCLC with EGFR L858R mutation in China.

Products and Pipeline

The following chart shows our drug candidates as of the date of this announcement:

	Product	Target	Indication	Regimen	Preclinical / IND-Enabling / Ph I/Ia / Ph Ib/II / Pivotal/ Registrational Ph II/Ph III	Current Status/ Upcoming Milestone	Commercial Rights/ Partner
Clinical Stage	TY-9591	3rd-Generation EGFR-TKI	NSCLC with brain metastasis (1L)	Mono	Ph Ib/II → Pivotal/ Registrational Ph II/Ph III	Preparing the NDA	China
			EGFR L858R NSCLC (1L)	Mono	Ph Ib/II → Pivotal/ Registrational Ph II/Ph III	Registrational Phase III ongoing	
			NSCLC (1L)	Combo	Ph Ib/II	Ph II ongoing	
	TY-302	CDK4/6	Breast cancer (2L+)	Combo	Ph Ib/II	Ph II ongoing	China
			Prostate cancer (1L)	Combo	Ph Ib/II	Ph II ongoing	
	TY-2136b	ROS1/NTRK	ROS1/NTRK-mutant solid tumor	Mono	Ph Ib/II	Ph Ib ongoing	Livzon (Greater China)
			ROS1/NTRK-mutant NSCLC	Mono	Ph I/Ia	Ph I ongoing	Ex-Greater China
	TY-2699a	CDK7	Breast cancer, Pancreatic cancer, Head and neck squamous cell carcinoma	Mono	Ph Ib/II	Ph Ib/II ongoing	Global
				Combo	IND-Enabling	IND approved	
	TY-0540	CDK2/4	Breast cancer, Ovarian cancer, Metastatic castration-resistant prostate cancer	Mono	Ph Ib/II	Ph Ib/II ongoing	Global
				Combo	Ph Ib/II	Ph Ib ongoing	
	TY-1091	RET	RET-fusion positive solid tumor, RET-mutation medullary thyroid cancer	Mono	Ph I/Ia	Ph I ongoing	Global
	TY-4028	EGFR Exon 20	EGFR exon 20 insertion NSCLC	Mono	IND-Enabling	IND approved	Global
	TY-1054	YAP-TEAD	Solid tumor	-	IND-Enabling	IND approved	Global
Preclinical Stage	CDK4	CDK4	Solid tumor	-	Preclinical	Preclinical Stage	Global
	EGFR (PROTAC)	EGFR (PROTAC)	NSCLC	-	Preclinical	Preclinical Stage	Global
	PI3Kα	PI3Kα	Solid tumor	-	Preclinical	Preclinical Stage	Global

Abbreviations: 1L = first line; 2L+ = third or later-line; EGFR = epidermal growth factor receptor; CDK = cyclin-dependent kinase; ROS1 = ROS proto-oncogene 1; NTRK = neurotrophic tyrosine receptor kinase; RET = rearranged during transfection; YAP = yes associated protein; TEAD = transcriptional enhanced associate domain; PROTAC = proteolysis-targeting chimera; NSCLC = non-small cell lung cancer; LC = lung cancer; Ph = Phase; NDA = new drug application.

Notes:

(1) The relevant intellectual property rights for TY-9591 and TY-302 were acquired from Changzhou Runnuo Biotechnology Co., Ltd. (常州潤諾生物科技有限公司) and Boji Medical Technology Co., Ltd. (博濟醫藥科技股份有限公司), and Tetranov Pharmaceutical, respectively. We have developed these two drug candidates at our own costs since preclinical stage. Except for these two drug candidates, all other drug candidates were internally discovered and developed by us.

(2) We have out-licensed the rights to develop, manufacture and commercialize TY-2136b in the Greater China to Livzon. We maintain the rights to develop and commercialize this drug candidate in the rest of the world.

Source: Company data

Our Products and Product Candidates

As a company focused on the development of small molecule targeted therapies for cancer treatment, we have built a pipeline with 11 drug candidates. An introduction to these products is listed below:

Core Product TY-9591 – A Third-Generation EGFR-TKI

TY-9591 is a tyrosine kinase inhibitor ("**TKI**") developed for patients with brain metastases from EGFR-mutated lung cancer and has outstanding efficacy for patients with brain metastases from EGFR-mutated lung cancer. TY-9591 can effectively cross the blood-brain barrier and irreversibly bind to EGFR mutants including exon 19 deletion, exon 21 L858R mutation, exon 19 deletion/T790M mutation, and L858R/T790M mutation, ultimately inhibiting the proliferation and metastasis of cancer cells. TY-9591 was developed through modifications of osimertinib to enhance its safety, allowing for a higher administration dosage and thus, potentially, improved efficacy. Specifically, TY-9591 was modified by replacing certain hydrogens in osimertinib with deuterium to reduce or slow down the breakdown of osimertinib. Such modification may retain the advantages of osimertinib, but also affect the way that osimertinib is metabolized, which may reduce the formation of the metabolite TY-9591-D1 (AZ5104). Based on preclinical studies, TY-9591-D1 (AZ5104) is showed to have much higher affinity to normal cells that express EGFR without mutations, and thus is the major cause of adverse events ("**AEs**") of TY-9591 and osimertinib. By reducing the production of TY-9591-D1, TY-9591 is expected to be safer than osimertinib and can be administered at a higher dose level, leading to improved antitumor efficacy and a higher level of blood-brain entry. In a Phase I clinical trial in healthy subjects, we investigated the mean drug metabolite concentration-time profiles after a single oral dose of 80mg TY-9591 and osimertinib in healthy subjects. Compared to osimertinib, the results showed an approximately 50% reduction in metabolite TY-9591-D1 exposure levels after TY-9591 administration, indicating that TY-9591 may have an improved safety profile than osimertinib. In addition, although not a head-to-head comparison, clinical data from our Phase Ib study showed that TY-9591 has demonstrated promising efficacy and safety profile with the median PFS of 21.5 months, confirmed objective response rate ("**ORR**") of 85.9% and confirmed disease control rate ("**DCR**") of 94.9% in lung cancer patients with EGFR mutations (L858R/exon 19 deletion).

We are currently investigating TY-9591 in brain metastases from lung cancer with EGFR mutations and in locally advanced (stage IIIb to IV) or metastatic lung cancer with EGFR L858R mutation. While there are a number of third-generation EGFR-TKIs approved for marketing in China and worldwide, no drug for brain metastases from lung cancer has been approved for marketing, demonstrating urgent unmet clinical needs. Results from our Phase Ib and Phase II clinical studies of TY-9591 monotherapy in advanced NSCLC have demonstrated a strong clinical efficacy. Among 29 evaluable lung cancer treatment-naïve patients with brain metastases enrolled in these studies, we observed that 25 patients reached intracranial partial response ("**PR**") and four reached complete response ("**CR**"), with an intracranial ORR of 100%. Although not a head-to-head comparison, this outcome outperformed the confirmed 77% intracranial ORR observed in NSCLC patients with brain metastases treated by osimertinib in the Phase III FLAURA trial. In the Phase II study, we observed that the overall incidence of serious adverse events ("**SAEs**") was only 8.3% and treatment-related SAEs was as low as 8.3%, demonstrating a favorable safety profile.

Based on the results from the pivotal Phase II registrational clinical trial, as of February 28, 2025, 257 EGFR-mutant NSCLC patients with brain metastases had been enrolled. Based on interim analysis of 224 patients, according to the RECIST assessment criteria, BICR-assessed iORR of asandeutertinib was 92.8% (95% CI: 86.3-96.8%) vs. 76.1% (95% CI: 67.2-83.6%) of osimertinib, P=0.0006; investigator-assessed iORR of asandeutertinib was 91.0% (95% CI: 84.1-95.6%) vs. 75.2% (95% CI: 66.2-82.9%) of osimertinib, P = 0.002. According to the RANO-BM assessment criteria, investigator-assessed confirmed iORRs were 90.1% (95% CI: 83.0%-94.9%) and 74.3% (95% CI: 65.3%-82.1%), P = 0.0023 in the asandeutertinib group and osimertinib group, respectively. Overall ORR favorable trended asandeutertinib with 84.7% comparing osimertinib with 75.2%. iPFS, PFS, OS, and other efficacy data were not yet mature.

The incidence of ≥Grade 3 treatment-related adverse events (TRAEs) was 31.5% in the asandeutertinib group vs. 15.0% in the osimertinib group. The most common ≥Grade 3 TRAEs with asandeutertinib included elevated creatine phosphokinase, QTcf interval prolongation, neutropenia, and leukopenia. Interstitial lung disease (ILD) occurred in 6.3% of patients, and QTcf prolongation occurred in 4.5% of patients. All AEs were manageable and could be monitorable.

Furthermore, TY-9591 may deliver improved efficacy as compared to osimertinib in lung cancer patients with the EGFR L858R mutation. Osimertinib exhibited a median progression-free survival ("**PFS**") of 18.9 months for both EGFR exon 19 deletion and L858R mutation. However, lung cancer patients with EGFR L858R mutation showed significantly shorter PFS of 14.4 months as compared to 21.4 months PFS observed in EGFR exon 19 deletion cases, according to the Phase III FLAURA study. Therefore, there exists an unmet clinical need to enhance the clinical outcomes for lung cancer patients with EGFR L858R mutation. Clinical data from our Phase Ib study showed that among lung cancer patients with EGFR L858R mutation, first-line TY-9591 treatment achieved a significantly prolonged median PFS as compared to osimertinib treatment in the Phase III FLAURA trial (19.3 months in 36 patients vs. 14.4 months in 104 patients) based on a non-head-to-head comparison. Since the PFS data for lung cancer patients with EGFR L858R mutation from the FLAURA China cohort is not publicly available, and the efficacy data from the FLAURA global cohort is generally better than that of the China cohort, we compared our clinical results with the data for lung cancer patients with EGFR L858R mutation from the FLAURA global cohort.

We commenced the subject enrollment for a pivotal Phase II clinical trial of TY-9591 monotherapy as first-line treatment in brain metastases from lung cancer with EGFR mutations in August 2023. In November 2024, we completed an enrollment of 224 patients that is qualified for conditional marketing approval (patient enrollment qualified for full marketing approval is still ongoing). We have submitted the relevant Pre-NDA in April 2025. We expect to formally submit an NDA application for conditional marketing in Q4 2025. In addition, we are conducting a registrational Phase III clinical trial of TY-9591 monotherapy as first-line treatment in locally advanced (stage IIIb to IV) or metastatic lung cancer with EGFR L858R mutation in China, for which we completed a patient enrollment of 541 subjects by the end of July 2025. We expect to complete the enrollment of all patients for this clinical trial in Q2 2026 and to submit NDA in 2028. To fully explore the potential of TY-9591, we also applied for and obtained IND approval for conducting Phase II and Phase III clinical trials of TY-9591 in combination with pemetrexed and cisplatin or carboplatin as first-line treatment in advanced or metastatic lung cancer with EGFR mutations in March 2024. Up to the date of this announcement, we did not receive any concerns or objections regarding our clinical development plans from the NMPA. We started the preparation for Phase II trial in November 2024 and officially initiated the site in February 2025. As of August 2025, patient enrollment has been completed. We expect to complete the preliminary data cleansing and analysis for the Phase II trial by Q4 2025 and to communicate with CDE for confirmatory clinical study in Q1 2026.

TY-302

TY-302 is a potent, selective oral cyclin-dependent kinase 4/6 ("**CDK4/6**") inhibitor developed for the treatment of advanced solid tumors, including breast cancer and prostate cancer. Targeting CDK4/6, a key cell cycle regulator, TY-302 suppresses the phosphorylation of retinoblastoma protein ("**Rb**"), preventing proliferation of cancer cells. TY-302 was modified by H/D exchange of palbociclib, the best-selling CDK4/6 inhibitor in the world. Based on the preliminary safety data collected through our current Phase I/II clinical trial, TY-302 achieved an improved safety profile in respect of AEs in general, especially AEs related to infectious disease, skin and subcutaneous tissue and GI system, based on a non-head-to-head comparison.

We are currently conducting a Phase II clinical trial of TY-302 for the treatment of breast cancer. We observed that TY-302 achieved a DCR of 71.4% in 14 enrolled breast cancer patients who had previously failed second-line or multiple lines of therapy. We expect to further investigate the combination therapy of TY-302 with toremifene in third – or later-line estrogen receptor positive ("**ER+**")/human epidermal growth factor receptor 2-negative ("**HER2-**") breast cancer that has progressed after second-line endocrine therapy. Breast cancer is the most common cancer in women, and its incidence rises with age, increasing year by year as women age. ER+/HER2 – breast cancer is the most common breast cancer subtype, accounting for approximately 70% of the patients.

Approval for a Phase II clinical trial of TY-302 in combination with abiraterone for the first-line treatment of prostate cancer was granted by the hospital ethics committee on July 10, 2025, and the trial was publicly registered on the CDE Clinical Trial Registration Platform on July 28, 2025. We explored TY-302 in combination with abiraterone for the treatment of metastatic castration-resistant prostate cancer ("**mCRPC**"), an advanced prostate cancer that is challenging to treat with and does not respond to the standard of care treatment, endocrine therapy. Prostate cancer is an epithelial malignant tumor of the prostate and the most common malignant tumor in the male genitourinary system. After receiving hormone therapy, almost all patients with advanced prostate cancer eventually develop CRPC, and mCRPC is the leading cause of death among them. The primary goals of treatment for mCRPC are symptom control and delaying progression.

TY-2136b

TY-2136b is an independently developed, oral ROS proto-oncogene 1 ("**ROS1**")/neurotrophic tyrosine receptor kinase ("**NTRK**") inhibitor used for the treatment of solid tumors. It was designed to efficiently bind with the active kinase conformation and avoid steric interference from a variety of clinically drug-resistant mutations. The compact structure is believed to allow TY-2136b to precisely and efficiently bind into the adenosine triphosphate ("**ATP**") binding pocket of the kinase, and potentially circumvent the steric interference that results in resistance to bulkier kinase inhibitors. Our current primary focus lies on NSCLC with ROS1 or NTRK mutation.

TY-2136b has demonstrated encouraging safety profile in preclinical studies. In addition, according to our preclinical data, TY-2136b is not only effective against ROS1/NTRK oncogenic gene mutations, but also exhibits high selectivity of ROS1 and NTRK mutations such as ROS1 G2032R mutation and NTRK G595R, which commonly contribute to resistance against existing ROS1/NTRK drugs. Specifically, despite its targeting multiple mutations, TY-2136b does not interfere with JAK/STAT signaling pathway, inhibit Ba/F3 cells overexpressing ABL1 (H396P) mutant kinase, or disrupt SRC kinase activity. In addition, its preliminary efficacy against ROS1 and NTRK mutations has been demonstrated across multiple animal models, showcasing its potential to address drug resistance against existing ROS1/NTRK drugs. As a result, the FDA has granted Orphan Drug Designation to TY-2136b for the treatment of ROS1-positive, NTRK fusion-positive, anaplastic lymphoma kinase ("**ALK**")-positive or leukocyte receptor tyrosine kinase ("**LTK**")-positive NSCLC. Furthermore, its potential has been recognized and endorsed by Livzon and we have out-licensed the Greater China rights of TY-2136b to Livzon.

We are conducting a Phase I clinical trial in the U.S. under the FDA's implied IND approval obtained in November 2021. Leveraging Phase I clinical data, we will communicate with the FDA and prudently design our future clinical development plan of TY-2136b in the U.S.

Other Pipeline Products

Our clinical products include the followings:

- TY-2699a is a selective CDK7 inhibitor designed for the treatment of advanced/metastatic solid tumors. Our preclinical studies showed that TY-2699a potentially has improved safety window with blood-brain barrier penetration capability. TY-2699a obtained implied IND approval from the FDA and IND approval from the NMPA in February 2023 and May 2023, respectively. We received NMPA approval for conducting clinical trials of TY-2699a under different administration regimens for the treatment of advanced/metastatic solid tumors (breast cancer, pancreatic cancer, nasopharyngeal carcinoma, and other head and neck squamous cell carcinomas) in January 2025. As of June 2025, we have completed the Phase I dose-escalation clinical trial of TY-2699a monotherapy in locally advanced or metastatic solid tumors (especially in HR+/HER2-breast cancer, triple-negative breast cancer (TNBC), SCLC, pancreatic cancer and head and neck cancer), while completing monotherapy dose-escalation studies in 7 dose groups (5mg, 10mg, 20mg, 40mg and 30mg, bid, continuous use; and 25 mg, 35 mg, bid, continuous use for 5 days followed by a 2-day break) involving a total of 30 patients. We carried out the extended study of monotherapy in triple-negative breast cancer (TNBC) in July 2025, with patient enrollment currently underway.

- TY-0540 is a selective CDK2/4 inhibitor intended for the treatment of breast cancer, ovarian cancer, prostate cancer and other solid tumors. We obtained implied IND approval from the FDA for conducting Phase I/II clinical trials of TY-0540 for the treatment of advanced solid tumors and IND approval from the NMPA for conducting Phase I clinical trials of TY-0540 in June 2023 and September 2023, respectively. A formal approval from the NMPA in February 2025 for the product to be used in the clinical trials of TY-0540 in combination with Fulvestrant (氟維司群) for the treatment in patients with locally advanced/recurrent metastatic breast cancer and the clinical trials of TY-0540 in combination with Enzalutamide (恩扎盧胺) for the treatment in patients with locally advanced/recurrent metastatic prostate cancer. In February 2025, the Phase I dose-escalation clinical trial of TY-0540 monotherapy for advanced solid tumors was completed, with dose-escalation studies completed for 5 dose groups (5mg, 10mg, 20mg, 30mg and 40mg, bid). At the Phase I dose-escalation stage, 24 patients were enrolled, including 15 with HR+/HER2- breast cancer, 5 with triple-negative breast cancer, 2 with platinum-resistant ovarian cancer, and 1 each with HR+/HER2+ breast

cancer and non-small cell lung cancer. 2 patients with CDK4/6 inhibitor-resistant HR+/HER2- breast cancer and 1 with platinum-resistant ovarian cancer achieved partial response (PR). The extended cohort studies of monotherapy (30mg) for breast cancer and ovarian cancer was officially initiated in March 2025 and the clinical study of TY-0540 in combination with Fulvestrant (氟維司群) for the treatment of breast cancer was officially initiated in June 2025. Approval for the clinical study of TY-0540 in combination with Enzalutamide (恩扎盧胺) for the treatment of prostate cancer was granted by the hospital ethics committee on July 10, 2025, and the study was publicly registered on the CDE Clinical Trial Registration Platform on July 25, 2025.

- TY-4028 is a potent, irreversible, oral exon 20 insertion-TKI, targeting locally advanced or metastatic NSCLC with EGFR exon 20 or HER2 exon 20 insertions. Patients with exon 20 insertions are associated with primary resistance to targeted EGFR-TKIs and correlate with poor patient prognosis. TY-4028 presents an innovative, targeted therapy for this specific subset of NSCLC patients. We obtained implied IND approval from the FDA and IND approval from the NMPA in April 2023 and June 2023, respectively.

- TY-1091 is a potent and selective rearranged during transfection proto-oncogene ("**RET**") inhibitor. It is intended for the treatment of advanced NSCLC with RET gene fusion, advanced medullary thyroid cancer ("**MTC**") with RET gene mutation and other advanced solid tumors with RET gene alterations. We obtained implied IND approval from the FDA and IND approval from the NMPA in August 2022 and December 2022, respectively.

- TY-1054 is a small molecule, oral YAP-TEAD inhibitor developed for cancer treatment. The Hippo pathway plays an essential role in cell proliferation, tissue regeneration, and tumorigenesis, the hyperactivation of which induces metastasis, chemoresistance, and the attribute of cancer stem cells. Its dysregulation contributes to 10% of all cancers, including lung cancer, gastric cancer, colon cancer, cervical cancer, ovarian cancer, breast cancer, melanoma, hepatocellular carcinoma and squamous cell carcinoma. The pathway is activated through binding of the YAP/TAZ complex to palmitoylated TEAD. Despite the urgent need to develop a therapeutic strategy to curb the dysregulated pathway, YAP/TAZ is difficult to be directly targeted with small molecule inhibitors, because of the lack of a catalytic niche. Therefore, targeting small molecules that block the palmitoylation of TEAD is an effective strategy. We obtained the implied approval from the FDA for conducting clinical trials of TY-1054 in solid tumors in April 2024. In addition, we submitted an IND application to the NMPA for conducting clinical trials of TY-1054 in solid tumors in April 2024, and obtained IND approval in July 2024.

In addition, we are developing a number of drug candidates in preclinical or early clinical development stage, including CDK4, EGFR(PROTAC) and PI3Kα.

Cautionary Statement as required by Rule 18A.08(3) of the Listing Rules: There is no guarantee that our Company will ultimately develop, market and/or commercialize TY-9591, TY-302, TY-2136b, TY-2699a, TY-0540, TY-4028, TY-1091, TY-1054, CDK4, EGFR(PROTAC), PI3Kα or any other product candidates successfully. Shareholders and potential investors of our Company are advised to exercise due care when dealing in the Shares.

Our Technology Platforms

We have established four proprietary and fully-integrated technology platforms centered around the development of new small molecule drugs, which enable us to direct our efforts towards candidates with the best potential to become clinically active, cost-effective and commercially viable drugs:

- **Drug design and screening platform:** Our drug design and screening platform is a small molecule drug discovery platform, currently focusing on kinase. This platform comprises two important functions, namely, kinase biology and small molecule drug discovery. Notably, all our drug candidates (except TY-9591 and TY-302) were conceived and synthesized within this platform, and have garnered recognition from domestic pharmaceutical companies. For example, we out-licensed the Greater China rights of TY-2136b to Livzon when it was in the preclinical stage.

- **Druggability evaluation platform:** Equipped with a druggability evaluation platform, we are capable of conducting a wide range of R&D activities in-house, including drug metabolism and pharmacokinetics ("**DMPK**") studies, in vivo and in vitro bioactivity studies (including animal modeling), toxicity studies, physicochemical characterization, and chemistry, manufacture, and controls processes ("**CMC**") of drug candidates. We are capable of evaluating the efficacy of our drug candidates including kinase inhibitors in-house.

- **Translational medicine platform:** Our translational medicine platform enables us to conduct research on the pathogenesis of tumors and neurological disorders, and systematically search for and identify potential biomarkers and new drug targets. Using genomics, transcriptomics and proteomics methods, we can systematically assess drug effects.

- **AIDD/CADD platform:** Our artificial intelligence drug design (AIDD)/computer-aided drug design (CADD) platform is dedicated to aiding our internal drug discovery team. The artificial intelligence drug design (AIDD) platform integrates cutting-edge computational methods and tools to enhance and refine the computing power and the construction of algorithmic systems. Leveraging extensive internal data and existing business strengths, the Company has expanded into the artificial intelligence drug design (AIDD) sector through a combination of in-house R&D and external collaborations. The project is progressing smoothly, with the local deployment of large language model (LLM) to be completed. Subsequent tasks, including algorithm optimization, training with the latest biomedical data, and application scenario development, will be carried out in a structured manner. AIDD/CADD platform has yielded several pipeline products. For example, TY-2136b, designed to target tyrosine kinases ROS1/NTRK, emerged during lead optimization in CADD. TY-2699a, a CDK7 inhibitor, employed AIDD/CADD in compound design, highlighting the value of AIDD in identifying overlooked aspects to improve therapeutic window.

RESEARCH AND DEVELOPMENT (R&D)

We consistently devote resources to R&D to pave way for long-term growth. Our R&D costs in the six months ended June 30, 2024 and six months ended June 30, 2025 amounted to RMB137.8 million and RMB88.8 million, respectively. Our in-house R&D capabilities, built on our proprietary technology platforms, are backed by our R&D centers in Huzhou, Zhejiang and Zhengzhou, Henan. Our R&D centers are equipped with advanced laboratories and state-of-art equipment and instruments such as liquid chromatography, liquid chromatography mass spectrometer, and nuclear magnetic resonance. We believe that our integrated capabilities give us the agility to formulate our innovation, registration, commercialization and product optimization strategies that can navigate us through rapidly changing market needs, enable us to improve pipeline viability and expedite the product development cycle at a lower cost. As of June 30, 2025, we had 113 members in our R&D team, around 56% of whom held master's or doctoral degrees in relevant fields. The expertise of our team members spans the entire spectrum of drug development, encompassing drug discovery, medicinal chemistry design and virtual screening, preclinical pharmaceutical research, drug testing and purification, formulation development, clinical research, regulatory submissions and platform construction.

COMMERCIALIZATION

Building upon the existing organizational structure, the Company is progressively expanding its commercialization team to tap into market potential by continuously exploring product sales opportunities and diversifying brand promotion efforts. Through participation in academic conferences, industry partnerships, and platform collaborations, the Company aims to elevate brand recognition within the industry in diversified brand promotion forms.

II. FINANCIAL REVIEW

Revenue

The Group's revenue basically depends on the proceeds generated pursuant to the exclusive license agreement (the "**Livzon Agreement**") with Livzon Pharmaceutical Group Inc. ("**Livzon**") to research, develop, improve, manufacture, use, sell, contract and commercialize ROS1/NTRK/ALK multi-target small molecule broad-spectrum tyrosine kinase inhibitor ("**TY-2136b**") in Greater China. The next milestone that would trigger payment obligation of Livzon had not been reached as of June 30, 2025.

Our revenue for the six months ended June 30, 2024 and the six months ended June 30, 2025 was RMB nil.

Cost of Sales

Our cost of sales for the six months ended June 30, 2024 and the six months ended June 30, 2025 was RMB nil.

Gross Profit and Gross Profit Margin

As a result of the reasons described above, our overall gross profit for the six months ended June 30, 2024 and the six months ended June 30, 2025 was RMB nil. The gross profit margin for the six months ended June 30, 2025 was nil.

Other Income and Gains

During the Reporting Period, our other income and gains primarily consisted of government grants, investment income on financial assets at FVTPL, bank interest income and foreign exchange losses, net.

The Group's other income and gains for the six months ended June 30, 2025 was RMB20,820,000, representing an increase of RMB9,535,000 compared to RMB11,285,000 for the six months ended June 30, 2024, mainly due to the increase in government grants related to income and investment income on financial assets at FVTPL.

Research and Development Costs

During the Reporting Period, our R&D costs consisted of (i) trial and testing expenses for our drug candidates, primarily in relation to the engagement of CROs, CDMOs, principal investigators, and other service providers; (ii) staff costs mainly relating to salaries, bonus and other welfare for our R&D personnel; (iii) depreciation and amortization expenses in relation to our R&D equipment and instruments, as well as intangible assets which were used for R&D purpose; (iv) costs of materials consumed in the course of our R&D activities; and (v) other R&D costs, mainly comprising travelling and transportation expenses of our R&D personnel, intellectual property costs and other miscellaneous expenses.

The Group's R&D costs for the six months ended June 30, 2025 was RMB88,758,000, representing a decrease of 35.6% compared to RMB137,758,000 for the six months ended June 30, 2024. The decrease was primarily attributable to the decrease in trial and testing expenses.

The following table sets forth a breakdown of our R&D costs for the Reporting Period as of the dates indicated:

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
Trial and testing expenses	**57,056**	99,601
Staff costs	**17,364**	20,295
Depreciation and amortization expenses	**8,383**	9,470
Materials consumed	**2,495**	1,342
Others	**3,460**	7,050
Total	**88,758**	137,758

Administrative Expenses

During the Reporting Period, our administrative expenses primarily consisted of (i) staff costs mainly relating to salaries, bonus and other welfare for our administrative personnel; (ii) professional service fees mainly paid to legal advisors, auditors, asset valuers and recruitment consultants; (iii) general office expenses mainly comprising office expenses, hospitality expenses, travelling and transportation expenses, and utilities used for administrative purpose; (iv) other administrative expenses, mainly including tax and surcharges and other miscellaneous expenses; and (v) depreciation and amortization expenses for offices, equipment and other assets which were used for administrative purpose.

The Group's administrative expenses for the six months ended June 30, 2025 was RMB38,775,000, representing a decrease of 3.3% compared to RMB40,100,000 for the six months ended June 30, 2024. The decrease was primarily attributable to the decrease in listing expenses.

Finance Costs

During the Reporting Period, our finance costs primarily consisted of (i) interest expenses on government funding; (ii) interest on bank loans; and (iii) interest on lease liabilities.

The Group's finance costs for the six months ended June 30, 2025 was RMB7,349,000, representing an increase of 35.3% compared to RMB5,431,000 for the six months ended June 30, 2024. The increase in finance costs was primarily attributable to the increase in interest on bank loans and interest expenses on government funding, partially offset by the decrease in interest on lease liabilities.

Other Expenses and Losses

Our other expenses and losses decreased from RMB70,000 for the six months ended June 30, 2024 to RMB3,000 for the six months ended June 30, 2025.

Income Tax Expenses

The Group did not generate any profits for the six months ended June 30, 2024 and 2025. Therefore, there was no income tax.

Loss for the Period

Based on the factors described above, our loss for the Reporting Period decreased from RMB219,533,000 for the six months ended June 30, 2024 to RMB114,065,000 for the six months ended June 30, 2025.

Liquidity and Capital Resources

As at June 30, 2025, the Group had cash and bank balances of RMB206,082,000, including, cash and cash equivalents of RMB131,082,000, term deposits with initial terms of more than 3 months of RMB50,000,000 and pledged deposits of RMB25,000,000. The cash and bank balances decreased by 55.2% compared to RMB460,463,000 as at December 31, 2024. The decrease was primarily due to the followings:

For the six months ended June 30, 2025, our net cash used in operating activities was RMB94,156,000, mainly attributable to (i) our loss before tax of RMB114,065,000, as adjusted to reflect non-cash and/or non-operating items, which principally included depreciation of right-of-use assets of RMB6,444,000, investment income on financial assets at FVTPL of RMB5,082,000, interest expenses on government grants of RMB4,550,000, government grants related to interest-free financing of RMB4,381,000, depreciation of fixed assets of RMB3,408,000, amortization of intangible assets of RMB2,829,000, and other finance costs of RMB2,799,000; (ii) a decrease in trade and other receivables of RMB14,357,000; and (iii) a decrease in trade and other payables of RMB6,665,000.

For the six months ended June 30, 2025, our net cash used in investing activities was RMB153,861,000, primarily attributable to the purchase of financial assets at FVTPL of RMB490,482,000, partially offset by the disposal of financial assets at FVTPL of RMB301,796,000 and the withdrawal of time deposits of RMB60,475,000.

For the six months ended June 30, 2025, our net cash generated from financing activities was RMB5,702,000, primarily as a result of new bank loans of RMB60,000,000, and borrowing from the non-controlling shareholder of RMB16,013,000 (representing proceeds from the Changxing Investment we received during the six months ended June 30, 2025), partially offset by repayment of bank loans of RMB65,280,000.

Treasury Policy

The Group has adopted a prudent financial management approach towards its treasury policy. The Board closely monitors the Group's liquidity position to ensure that the liquidity structure of the Group's assets, liabilities, and other commitments can meet its funding requirements all the time.

Capital Expenditure

During the Reporting Period, the Group's total capital expenditures amounted to approximately RMB(24,408,000), which was mainly the refund of payments used for the purchases of items of property, plant and equipment.

We regularly incur capital expenditures to purchase and maintain our property, plant and equipment in order to enhance our research and development capabilities and expand our business operations. Historically, we have funded our capital expenditures mainly through equity financing and bank borrowings.

Borrowings

As at June 30, 2025, our borrowings were RMB138,861,000, and as at December 31, 2024, our borrowings were RMB144,175,000. The borrowings were secured and unsecured short-term bank loans from various commercial banks, with effective interest rates ranging from 2.90% to 3.45% per annum. Among them, RMB63,801,000 was fixed-rate loans, and RMB75,060,000 was floating-rate loans. As at June 30, 2025, the Group had RMB10,000,000 of unutilized bank facilities available. As at June 30, 2025, the Group's gearing ratio (total liabilities as a percentage of total assets) was approximately 54.9%, compared to approximately 48.4% as at December 31, 2024.

Commitments

The Group had the following contractual commitments as of the end of the Reporting Period:

	June 30, 2025	December 31, 2024
	RMB'000	*RMB'000*
Property, plant and equipment	**28,816**	36,433

Pledge of Assets

As of June 30, 2025, save for the pledge of certain deposit of the Group as security for the Group's borrowings, the Group did not have any major assets pledged.

Contingent Liabilities

As of June 30, 2025, the Group did not have any material contingent liabilities.

Material Acquisitions and Disposals of Subsidiaries, Associates and Joint Ventures

On April 24, 2025, the Company, Tengyuan Changxing, Huzhou Innovation, Huzhou Industrial Investment, Changxing Xingqiang Investment and Shanghai Younan entered into the Joint Venture Agreement, pursuant to which the parties agreed to establish the Fund and the Company will participate in the newly formed Fund as a limited partner. Pursuant to the Joint Venture Agreement, the Company agreed to invest RMB18.0 million in the Fund. Dr. Wu Yusheng, the chairman of the Board and chief executive officer of the Company is indirectly interested in Tengyuan Changxing, a general partner to the Fund. Therefore, Tengyuan Changxing is a connected person of the Company under Rule 14A.07 of the Listing Rules. Accordingly, the entering into of the Joint Venture Agreement constitutes a connected transaction of the Company under Chapter 14A of the Listing Rules. Please refer to the announcement of the Company dated April 24, 2025 for further details.

Save as disclosed in this announcement and the Prospectus, as at June 30, 2025, did not make any other material acquisition or investment. For the Reporting Period, except for the potential disposal of the entire equity interest in a subsidiary to an Independent Third Party before our Listing with a consideration of RMB34,900,000 which we are still in the process of completing this transaction, the Group did not have material acquisitions or disposals.

Foreign Currency Risk

The Group was not exposed to significant currency risk, and did not experience any material impact on our operations resulting from fluctuation in exchange rates during the Reporting Period. However, our management monitors our foreign currency risk exposure and will review and adjust our currency risk measures in accordance with our needs. During the Reporting Period, we did not hedge against any foreign exchange fluctuations.

Employees and Remuneration Policies

As of June 30, 2025, we have a total of 163 employees (as of June 30, 2024: 144 employees). The remuneration package of our employees includes basic salaries, bonuses, and employee benefits, which are generally determined by their qualifications, industry experience, position and performance. We make contributions to social insurance and housing provident funds as required by the PRC laws and regulations. In addition, we provide relevant training to our employees in order to improve their skills and knowledge. We have also adopted the Employee Incentive Scheme in recognition of the contribution of our employees. In addition, we provide relevant training to our employees in order to improve their skills and knowledge.

Future Plan for Material Investments or Acquisition of Assets

Save as disclosed in the Prospectus, the Group did not have detailed future plans for any material investments or acquisition of capital assets as of the date of this announcement.

III. FUTURE AND OUTLOOK

Continuously enhance R&D capabilities and drive business development

Our core competitiveness lies in our understanding of diseases and the mechanisms of drug action. To date, we have achieved remarkable results, and in the future, we will continue to strengthen these capabilities. Meanwhile, we recognize that drugs with new targets and mechanisms of action will enhance our competitiveness in the pharmaceutical industry. Therefore, we have developed several innovative candidate drugs targeting the following relevant targets: CDK4, EGFR(PROTAC), and PI3Ka, and plan to continue developing these candidates. Additionally, we plan to actively invest in in-house R&D to seize market opportunities and identify and develop innovative compounds.

With the rapid development of antibody – drug conjugate (ADC) technology, traditional ADC strategies mainly rely on highly toxic chemical toxins as drug payloads. However, the mechanism of action of such toxins is relatively single, and their toxicity is often difficult to precisely control, which may lead to off-target toxicity and safety risks. To overcome the limitations of traditional ADCs, based on our profound experience in small molecule drug development, the Company will embark on the development of a new generation of ADCs. We will make full use of innovative technologies such as highly active small molecule inhibitors, PROTAC (proteolysis-targeting chimeras), and molecular glues, and combine them with the mature antibody technologies in the market to create more efficient and safer next-generation ADCs.

We expect that the next-generation ADC drugs, with their precise targeting and innovative design of small molecule payloads, will break through the boundaries of traditional ADCs in tumor treatment and expand into a wider range of unmet clinical needs. The next-generation ADCs will redefine the boundaries of "targeted therapy" - from oncology to chronic diseases, and from cell killing to functional regulation. Through the in-depth integration of small molecule technologies (such as highly active small molecule inhibition and the catalytic degradation properties of PROTAC and molecular glues), we are expected to provide transformative solutions for diseases that are beyond the reach of traditional therapies. We have established a subsidiary specializing in large molecule drug development, through which we will develop a pipeline of innovative drug products such as bispecific antibodies, trispecific antibodies and ADCs (including those targeting oncology and autoimmune diseases).

Incorporate artificial intelligence models and gradually build an industrial production system

The Company will maintain a relentless focus on market demands, driving R&D innovation in self-developed cutting-edge products. By leveraging technological empowerment of artificial intelligence models, the Company will deepen collaborations between our internal teams and top foreign teams to efficiently promote the development of new molecules. Concurrently, relying on our internal teams and proactive collaboration with external AI-driven drug discovery platforms, the Company is committed to achieving more breakthroughs in drug R&D, thereby further enhancing R&D efficiency and core value, injecting new impetus into the upgrading and development of our business, and ultimately supporting the Company in achieving its long-term goal of sustainable development. The "New Solid Dosage Form Factory Project" is an industrialization project of the Company, which adds tablet and capsule production lines. After the completion of this project, the Company's annual production capacity can reach 150 million tablets or capsules, meeting the production requirements for clinical drugs and partial commercialization of the TY-9591 product. The civil engineering of the first phase project passed the completion acceptance on June 30, 2024. It is expected that the production lines of the first phase construction will obtain GMP compliance certification by 2026 and be ready for production. We believe that the completion of this project will provide production support for the commercialization of more pipeline products.

Explore partnership opportunities and establish commercialization capability to increase the value of our drug candidates

We plan to continue to actively explore business collaboration opportunities with leading industry participants to accelerate our development timelines and maximize the clinical and commercial value of our drug candidates in other key international markets. For example, we will consider forging partnerships with multinational corporations to out-license the overseas rights of our assets as and when appropriate.

Meanwhile, we plan to enhance our business development team, which will continue to closely monitor and keep abreast of the evolving clinical demands, to pursue global opportunities to in-license new drug candidates. We may also selectively acquire or invest in innovative technologies to enhance our R&D capabilities or explore potential combination therapy partners for TY-9591. We will emphasize on assets that have potential synergies with our current pipeline and technology pipeline, and/or have best-in-class and/or first-in-class potential.

The Company's commercialization team has been preliminarily established, with core management members possessing extensive experience in promotion and commercialization operations. Moving forward, the Company will steadily advance the systematic construction of the team to precisely align with full-scenario commercial promotion needs. The Company will continue to integrate its multi-dimensional advantages in capital, talent, and technology, to improve the functional layout of its clinical research platform and accelerate the construction of its industrialization base, promoting the commercialization process. This dual-engine approach will drive the commercialization process forward. Meanwhile, we plan to systematically establish a sales and marketing system through a combination of in-house efforts and working with external partners. By leveraging our partners' mature market expertise, extensive channel networks, and robust resource reserves, we aim to create a powerful commercial synergy that capitalizes on our complementary advantages.

OTHER INFORMATION

INTERIM DIVIDEND

The Board does not recommend the payment of an interim dividend for the Reporting Period (for the six months ended June 30, 2024: Nil).

CORPORATE GOVERNANCE

We are committed to achieving high standards of corporate governance with a view to safeguarding the interest of our Shareholders. The Company has adopted the CG Code as its own code of corporate governance after the Listing.

During the Reporting Period, the Company has complied with all the code provisions as set out in Part 2 of the CG Code, save and except for the following deviation:

Under paragraph C.2.1 of Part 2 of the CG Code, the roles of chairperson and chief executive officer should be separate and should not be performed by the same individual. Dr. WU Yusheng ("**Dr. Wu**") is the chairperson of the Board and the chief executive officer of the Company. With abundant experience in the pharmaceutical industry and having served in the Company since its establishment, Dr. Wu is in charge of overseeing the overall management, business operation and strategies of the Group. Despite the fact that the roles of the chairperson of the Board and the chief executive officer of the Company are both performed by Dr. Wu, which constitutes a deviation from paragraph C.2.1 of Part 2 of the CG Code, the Board considers that vesting the roles of both the chairperson of the Board and the chief executive officer of the Company all in Dr. Wu has the benefit of ensuring consistent leadership and more effective and efficient overall strategic planning of the Company.

The balance of power and authority is ensured by the operation of the Board and the senior management, each of which comprises experienced and diverse individuals. Following the resignation of Dr. MENG Xiaoying (孟曉英) as a non-executive Director, the Board currently comprises one executive Director, five non-executive Directors and four independent non-executive Directors. Therefore, the Board possesses a strong independence element in its composition. The Board will continue to review the effectiveness of the corporate governance structure of the Group in order to assess whether separation of the roles of chairperson and the chief executive officer is necessary.

The Company will continue to review and monitor our corporate governance practices regularly to ensure compliance with the CG Code and to maintain high standards of corporate governance practices.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS

During the Reporting Period, the Company has adopted the Model Code as its own code of conduct regarding dealings in the securities of the Company by the Directors and the Supervisors.

On August 20, 2025, Pivot Pharma Tech (Shanghai) Co., Ltd. (貝沃特醫藥技術(上海)有限公司), a company wholly-owned by Dr. GU Eric Hong ("**Dr. Gu**"), entered into an on-market transaction disposing of a total of 10,000 H Shares at a consideration of HK$14.99 per H Share (the "**Transfer**") without first having notified the Company prior to the Transfer in accordance with the requirements paragraph B.8 of Appendix C3 to the Listing Rules. The Transfer fell within the Black-out Period and constituted a dealing of Shares by Dr. Gu and a non-compliance incident of paragraphs A.3 and B.8 of Appendix C3 to the Listing Rules (the "**Non-compliance Incident**"). Dr. Gu reported the Non-compliance Incident to the Company and confirmed that the non-compliance was an inadvertent oversight and he did not intend to commit such breach. Dr. Gu further confirmed that he does not possess any inside information of the Company when the Transfer took place. For further details, please refer to the announcement of the Company dated August 21, 2025.

Upon specific enquiries, except for the aforementioned, all Directors and Supervisors confirmed that they have complied with the Model Code during the Reporting Period and up to the date of this announcement.

Relevant employees of the Company who may have access to the Company's inside information are also required to comply with the Model Code for securities transactions. During the Reporting Period, the Company has not noticed any incidents of relevant employees of the Company violating the Model Code.

The Company also refers to its announcement dated August 21, 2025, where it was made aware of breaches of the paragraphs A.3 and B.8 of the Model Code in relation to the dealings of 10,000 H Shares by an entity controlled by Dr. GU Eric Hong, a non-executive Director. As disclosed in the announcement, upon becoming aware of the incident, the Company has immediately reminded the Directors and senior management again of the requirements of the Model Code and the importance of compliance with such provision.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES OF THE COMPANY

During the Reporting Period, none of the Company or any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities (including sale of treasury Shares). As of June 30, 2025, the Company did not hold any treasury Shares.

MATERIAL EVENTS AFTER THE REPORT PERIOD

Full Circulation

The Company has submitted an application (the "**Application**") to the CSRC on June 6, 2025, in respect of the conversion of 4,608,000 Unlisted Shares into H Shares and the listing of such shares on the Stock Exchange (the "**H Share Full Circulation**"). As of the date of this announcement, the Company has not completed the filing with the CSRC in respect of the Application. The H Share Full Circulation is subject to other relevant procedures as required by the CSRC, the Stock Exchange and other domestic and overseas regulatory authorities. Further announcement(s) will be made on the progress and details of the Application and the H Share Full Circulation as and when appropriate.

Please refer to the announcement of the Company dated June 6, 2025 for further details.

Placing of New H Shares

The new Shares will be allotted and issued by the Company pursuant to the general mandate granted to the Board by special resolution of the Shareholders passed at the annual general meeting held on June 26, 2025, under which the Board may allot, issue and deal with new Shares not exceeding 74,167,163 new Shares (representing approximately 20% of the issued Shares as at the date of the passing of the resolution at the AGM). The Company entered into the Placing Agreement with CLSA Limited on July 28, 2025. All the conditions set out in the Placing Agreement had been fulfilled and the Completion took place on August 4, 2025. An aggregate of 9,230,000 Placing Shares have been successfully placed by the Placing Agent at the Placing Price of HK$17.01 per Placing Share to not less than six Placees. Please refer to the announcements of the Company dated July 29, 2025 and August 4, 2025 for further details.

Save as disclosed above, the Group did not have any other material subsequent events after the Reporting Period and up to the date of this announcement.

REVIEW OF INTERIM RESULTS

The Board has established the Audit Committee which consists of one non-executive Director, namely, Dr. LI Jun (李鈞) and two independent non-executive Directors, namely, Mr. ZHANG Senquan (張森泉) and Dr. LENG Yuting (冷瑜婷). The chairperson of the Audit Committee is Mr. ZHANG Senquan, who holds the appropriate professional qualifications as required under Rules 3.10(2) of the Listing Rules.

The Audit Committee has reviewed and considered that the unaudited interim condensed consolidated financial information of the Group for the six months ended June 30, 2025 are in compliance with the relevant accounting standards, rules and regulations and appropriate disclosures have been duly made.

PUBLICATION OF THE 2025 CONDENSED CONSOLIDATED INTERIM RESULTS AND INTERIM REPORT

This interim results announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.tykmedicines.com). The 2025 interim report of the Company containing all the information required by the Listing Rules will be published on the respective websites of the Stock Exchange and the Company and despatched to the Shareholders (upon request) in due course.

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The Board hereby announces that Dr. MENG Xiaoying ("**Dr. MENG**") has tendered her resignation as a non-executive Director of the Company, with effect from August 31, 2025, in order to devote more time to other business commitments. Dr. MENG confirmed that she has no claim against the Company in respect of her resignation and has no disagreement with the Board and the Company.

Dr. MENG further confirmed that there is no other matter in relation to her resignation that should be brought to the attention of the Shareholders and the Stock Exchange.

The Board would like to express its sincere gratitude and appreciation to Dr. MENG for her valuable contributions to the Company during her tenure of services as a non-executive Director.

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Pursuant to Rule 13.51(1) of the Listing Rules, the Board hereby announces that the Board has proposed to make the following amendments to the existing Articles of Association (the "**Proposed Amendments to the Articles**"), for the purposes of, among others, (i) change in the Company's registered capital; (ii) change in total number of board members; and (iii) change in total number of vice presidents.

Articles before amendment	Articles after amendment
Article 6 The registered capital of the Company is RMB370.835818 million.	**Article 6** The registered capital of the Company is RMB~~370.835818~~380.065818 million.
Article 109 The Board of Directors consists of 11 members, 4 of whom are independent non-executive Directors. At any time, the Board of Directors shall consist of more than 1/3 independent non-executive Directors. The Board of Directors shall have a chairperson and no vice-chairperson.	**Article 109** The Board of Directors consists of ~~11~~10 members, 4 of whom are independent non-executive Directors. At any time, the Board of Directors shall consist of more than 1/3 independent non-executive Directors. The Board of Directors shall have a chairperson and no vice-chairperson.

Articles before amendment	Articles after amendment
Article 128 The Company shall have a chief executive officer, who shall be appointed or dismissed by the Board of Directors. The Company shall have four vice presidents and a financial officer, all of whom shall be appointed or dismissed by the Board of Directors. The chief executive officer, vice president, financial officer and secretary to the Board of Directors of the Company are the senior management of the Company.	**Article 128** The Company shall have a chief executive officer, who shall be appointed or dismissed by the Board of Directors. The Company shall have ~~four~~three vice presidents and a financial officer, all of whom shall be appointed or dismissed by the Board of Directors. The chief executive officer, vice president, financial officer and secretary to the Board of Directors of the Company are the senior management of the Company.

Save as disclosed above, the contents of the other articles of the Articles of Association remain unchanged. The Proposed Amendments to the Articles are subject to the consideration and approval of the Shareholders by way of a special resolution at the extraordinary general meeting and will become effective upon approval by the Shareholders at the extraordinary general meeting. A circular containing, among others, details in respect of the Proposed Amendments to the Articles, together with the notice of the extraordinary general meeting and the related proxy form, will be sent to the Shareholders in the manner as they elect to receive corporate communications and published on the websites of the Stock Exchange and the Company in due course.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings.

"Articles of Association"	the articles of association of the Company currently in force
"Audit Committee"	the audit committee of the Board
"Board"	the board of Directors
"Board of Supervisors"	the board of Supervisors
"CG Code"	the Corporate Governance Code as set out in Appendix C1 to the Listing Rules
"China" or "the PRC"	the People's Republic of China, excluding, for the purposes of this announcement, Hong Kong, the Macau Special Administrative Region of the People's Republic of China and Taiwan
"Company" or "the Company"	TYK Medicines, Inc* (浙江同源康醫藥股份有限公司), a joint stock company incorporated in the PRC with limited liability on November 2, 2017
"Director(s)"	the director(s) of the Company or any one of them

"Group", "our Group", "our", "we", or "us"	the Company and its subsidiaries, or any one of them as the context may require or, where the context refers to any time prior to its incorporation, the business which its predecessors or the predecessors of its present subsidiaries, or any one of them as the context may require, were or was engaged in and which were subsequently assumed by it
"CSRS"	China Securities Regulatory Commission
"H Share(s)"	ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, which are subscribed for and traded in Hong Kong dollars and listed on the Stock Exchange
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"HK$"	Hong Kong dollars and cents, respectively, the lawful currency of Hong Kong
"Listing"	listing of the H Shares on the Main Board of the Stock Exchange
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange (as amended, supplemented or otherwise modified from time to time)
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules
"Main Board"	the stock market (excluding the option market) operated by the Hong Kong Stock Exchange which is independent from and operated in parallel with the GEM of the Stock Exchange
"Prospectus"	the prospectus of the Company dated August 12, 2024
"Reporting Period"	the six months ended June 30, 2025
"RMB"	the lawful currency of the PRC
"Share(s)"	ordinary share(s) in the capital of the Company with a nominal value of RMB1.00 each, including both Unlisted Share(s) and H Share(s)
"Shareholder(s)"	holder(s) of the Share(s)
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"subsidiary(ies)"	has the meaning ascribed thereto under the Listing Rules
"Supervisor(s)"	member(s) of the Supervisory Committee
"Tetranov Pharmaceutical"	Tetranov Pharmaceutical (Zhengzhou) Co., Ltd. (鄭州泰基鴻諾醫藥股份有限公司) (formerly known as Tetranov Pharmaceutical Technology (Zhengzhou) Co., Limited (鄭州泰基鴻諾藥物科技有限公司)), a company incorporated in the PRC with limited liability on November 26, 2007 and one of our controlling shareholders

"Changxing KY"	Kangyuan Pharmaceuticals (Changxing) Co., Ltd. (長興康源製藥有限公司), a company established in the PRC on March 25, 2021, and a non-wholly owned subsidiary of the Company
"Changxing Xingqiang Investment"	Changxing Xingqiang Chuangqiang Investment Partnership (Limited Partnership) (長興興長創強投資合夥企業(有限合夥)), a limited partnership established in the PRC and an Independent Third Party, and a limited partner of the Fund pursuant to the Joint Venture Agreement
"Huzhou Industrial Investment"	Huzhou Industrial Investment Fund Co., Ltd. (湖州市產業基金投資有限公司), a company incorporated in the PRC with limited liability and an Independent Third Party, and a limited partner of the Fund pursuant to the Joint Venture Agreement
"Huzhou Innovation"	Huzhou Innovation Incubation Investment Co., Ltd. (湖州市創新創業投資有限公司), a company incorporated in the PRC with limited liability and an Independent Third Party, and a general partner of the Fund pursuant to the Joint Venture Agreement
"Shanghai Younan"	Shanghai Younan Environmental Protection Technology Co., Ltd. (上海友南環保科技有限公司), a company incorporated in the PRC with limited liability and an Independent Third Party, and a limited partner of the Fund pursuant to the Joint Venture Agreement
"Tengyuan Changxing"	Tengyuan (Changxing) Investment Management Co., Ltd. (騰遠(長興)投資管理有限公司), a company incorporated in the PRC with limited liability and an associate of Mr. Wu Yusheng, an executive Director and controlling shareholder of the Company, and a general partner of the Fund pursuant to the Joint Venture Agreement
"Unlisted Share(s)"	ordinary share(s) issued by the Company with a nominal value of RMB1.00 each and are not listed on any stock exchange
"USD"	United States dollars, the lawful currency of the United States
"%"	per cent

By order of the Board
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)
Dr. WU Yusheng
Chairman, Executive Director and Chief Executive Officer

Hong Kong, August 31, 2025

As at the date of this announcement, the Board comprises Dr. WU Yusheng as executive Director, Dr. LI Jun, Dr. GU Eric Hong, Dr. JIANG Mingyu, Mr. HE Chao and Dr. ZHU Xiangyang as non-executive Directors, and Mr. ZHANG Senquan, Dr. LENG Yuting, Dr. XU Wenqing and Dr. SHEN Xiuhua as independent non-executive Directors.